Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
American medicine is fast descending into lethal medicine thanks to FDA officials who lend the government seal of approval to drugs and experiments that kill.
The Texas whistleblower lawsuit against Johnson & Johnson promises to topple the house of cards upon which the public mental health system rests.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
See: http://ahrp.blogspot.com/2007/01/big-bucks-big-pharma-documentary-video.html And see, PDUFA-Payola see: http://pharmamkting.blogspot.com/
State Attorney Generals are investigating the off-label marketing of Zyprexa–which, if documented is a federal crime. Continue reading →
The New York Times is calling for congressional hearings after the revelations that Eli LillyDocumented evidence reveal that Eli Lilly glossed over the debilitating hazards of Zyprexa–and aggressively marketed it to primary care physicians. Continue reading →
"Most off-label use occurs without scientific support." Continue reading →
Neuroscientists are venturing into new areas positing that through attentive thinking (meditating) we can reshape the hard drive of our brains.
The New York Times calls for congressional hearings into marketing of Zyprexa. Continue reading →
The New York Times reports that internal marketing documents show that “Eli Lilly encouraged primary care physicians to use Zyprexa, in patients who did not have either condition.”
Read Transcript of Hearing: http://ahrp.blogspot.com/2007/01/zyprexa-litigation-hearing-judge-jack.html Continue reading →